Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Spontaneous Resolution of Acute Rejection and Tolerance Induction With IL-2 Fusion Protein in Vascularized Composite Allotransplantation

(2015) R. Jindal et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2

(2015) Eric F. Zhu et al.   CANCER CELL

Challenges and opportunities for non-antibody scaffold drugs

(2015) Rodrigo Vazquez-Lombardi et al.   DRUG DISCOVERY TODAY

Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps

(2015) Suman Mitra et al.   IMMUNITY

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

(2015) Charles J.M. Bell et al.   JOURNAL OF AUTOIMMUNITY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

IL-7/Anti-IL-7 mAb Complexes Restore T Cell Development and Induce Homeostatic T Cell Expansion without Lymphopenia

(2014) O. Boyman et al.   JOURNAL OF IMMUNOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2

(2013) T. Carmenate et al.   JOURNAL OF IMMUNOLOGY

Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates

(2012) Timothy Millington et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Differential Effects of Denileukin Diftitox IL-2 Immunotoxin on NK and Regulatory T Cells in Nonhuman Primates

(2012) Y. Yamada et al.   JOURNAL OF IMMUNOLOGY

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Efficient Treg depletion induces T-cell infiltration and rejection of large tumors

(2010) Xingrui Li et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor   subunit CD25

(2010) S. Letourneau et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells

(2009) David V. Liu et al.   JOURNAL OF IMMUNOTHERAPY

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL

Transient T cell depletion causes regression of melanoma metastases

(2008) Mary Rasku et al.   Journal of Translational Medicine